"This time you can really look forward to it"... Why HLB is confident about its fourth attempt with liver cancer drug
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Management confidence on the liver cancer drug repeats prior pipeline commentary; no new event.